<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29236" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sotalol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mubarik</surname>
            <given-names>Ateeq</given-names>
          </name>
          <aff>Oak hill hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kerndt</surname>
            <given-names>Connor C.</given-names>
          </name>
          <aff>Spectrum Health/Michigan State University College of Human Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cassagnol</surname>
            <given-names>Manouchkathe</given-names>
          </name>
          <aff>St. John's University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ateeq Mubarik declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Connor Kerndt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29236.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Sotalol is a non-cardioselective &#x003b2;-blocker that possesses potassium channel-blocking properties. Due to&#x000a0;the predominant potassium channel&#x02013;blocking effect, this drug is classified as a class III agent in the Vaughan-Williams classification system for antiarrhythmic medications. Sotalol is approved by the US Food and Drug Administration (FDA) and is indicated for treating hemodynamically stable ventricular tachycardia, as well as maintaining sinus rhythm, particularly in cases of paroxysmal atrial fibrillation. Intravenous loading of sotalol is recommended to facilitate the initiation of oral sotalol therapy.</p>
        <p>Sotalol is also used as an off-label medication for&#x000a0;pharmacological cardioversion of atrial fibrillation, premature ventricular contractions, postoperative atrial fibrillation after cardiac surgery,&#x000a0;and supraventricular tachycardia (SVT). Sotalol is also used off-label in transplacental isolated sotalol therapy or in combination with digoxin for treating fetal&#x000a0;SVT and atrial fibrillation, resulting in 85% complete or partial resolution.&#x000a0;This activity provides a comprehensive overview of the indications, mechanisms of action, administration methods, significant adverse effects, contraindications, and monitoring protocols of sotalol, assisting clinicians in directing patient therapy effectively within the interprofessional healthcare team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate candidates for sotalol therapy based on indications such as hemodynamically stable ventricular tachycardia and paroxysmal atrial fibrillation.</p></list-item><list-item><p>Implement appropriate dosing strategies for sotalol initiation, considering patient-specific factors and clinical indications.</p></list-item><list-item><p>Select alternative treatment options or adjust sotalol dosing in patients experiencing adverse effects or inadequate therapeutic response.</p></list-item><list-item><p>Collaborate with other healthcare professionals, including pharmacists and cardiologists, to provide holistic and patient-centered management of cardiac arrhythmias with sotalol therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29236&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29236">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29236.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Sotalol is a non-cardioselective &#x003b2;-blocker that possesses potassium channel-blocking properties. Sotalol is approved by the US Food and Drug Administration (FDA) and is indicated for treating the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hemodynamically stable ventricular tachycardia.<xref ref-type="bibr" rid="article-29236.r1">[1]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Maintaining sinus rhythm,&#x000a0;particularly in cases of paroxysmal atrial fibrillation.<xref ref-type="bibr" rid="article-29236.r2">[2]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intravenous (IV) loading of sotalol to facilitate the initiation of oral sotalol therapy.<xref ref-type="bibr" rid="article-29236.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Sotalol is also used as an off-label medication for the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of premature ventricular contractions.<xref ref-type="bibr" rid="article-29236.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pharmacological cardioversion of atrial fibrillation, albeit with reduced effectiveness.<xref ref-type="bibr" rid="article-29236.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Management of postoperative atrial fibrillation following cardiac surgery.<xref ref-type="bibr" rid="article-29236.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Administration for supraventricular tachycardia (SVT), particularly via IV route.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Utilization in transplacental isolated sotalol therapy or in combination with digoxin for treating fetal SVT and atrial fibrillation, resulting in 85% complete or partial resolution.<xref ref-type="bibr" rid="article-29236.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>No difference is apparent between sotalol and amiodarone regarding the pharmacological conversion of atrial&#x000a0;fibrillation.<xref ref-type="bibr" rid="article-29236.r8">[8]</xref><xref ref-type="bibr" rid="article-29236.r9">[9]</xref>&#x000a0;The recurrence rate of atrial&#x000a0;fibrillation&#x000a0;is higher for sotalol than amiodarone, except in patients with ischemic heart&#x000a0;disease.<xref ref-type="bibr" rid="article-29236.r8">[8]</xref><xref ref-type="bibr" rid="article-29236.r9">[9]</xref>&#x000a0;Sotalol&#x000a0;has not demonstrated any beneficial effect as prophylaxis with an automatic implantable cardioverter defibrillator (AICD) to prevent ventricular arrhythmias&#x000a0;in stopping appropriate or inappropriate ICD shocks; in this scenario, amiodarone is better than sotalol.</p>
        <p>According to the Heart Rythm Society (HRS) guidelines, sotalol may be reasonable in&#x000a0;patients with arrhythmogenic cardiomyopathy to control arrhythmic symptoms or decrease cardioverter defibrillator (ICD) shocks; however, amiodarone is preferred over sotalol. According to the HRS, sotalol may also be&#x000a0;appropriate in patients&#x000a0;with cardiac amyloidosis and symptomatic atrial arrhythmias.<xref ref-type="bibr" rid="article-29236.r10">[10]</xref>&#x000a0;</p>
        <p>According to the recent Dashboard Activated Services and Telehealth for Heart Failure (DASH-HF) trial published in the Journal of the American College of Cardiology, rapid IV sotalol loading is feasible and safe compared to conventional oral loading protocols. This approach provides advantages such as reduced hospital stays, enhanced patient convenience, and savings for patients and healthcare systems. However, the DASH-atrial fibrillation (AF) trial had&#x000a0;limitations, including&#x000a0;the small nonrandomized design and inadequate statistical power to detect variances in ventricular pro-arrhythmia or mortality rates between the groups receiving IV sotalol loading and oral sotalol.<xref ref-type="bibr" rid="article-29236.r11">[11]</xref></p>
      </sec>
      <sec id="article-29236.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Sotalol is a non-cardioselective &#x003b2;-blocker that possesses potassium channel-blocking properties. Due to&#x000a0;the predominant potassium channel&#x02013;blocking effect, this drug is classified as a class III agent in the Vaughan-Williams classification system for antiarrhythmic medications. Sotalol&#x000a0;prolongs the action potential duration and effective refractory period in the atrium, ventricle, and nodal and extranodal tissue.&#x000a0;This agent&#x000a0;is a potent competitive inhibitor of potassium&#x000a0;current.</p>
        <p>Sotalol exhibits reverse use-dependent effects, meaning the maximal potassium current blocking impact occurs when the heart rate is slow, increasing the risk of QT prolongation and torsades de pointes&#x000a0;in bradycardic conditions. Although a low dose of sotalol (25 mg) is adequate to exert a &#x003b2;-blocking effect, a higher dose (up to 80 mg) is necessary for class III antiarrhythmic effects.<xref ref-type="bibr" rid="article-29236.r12">[12]</xref>&#x000a0;</p>
        <p>According to current research, the human Ether-&#x000e0;-go-go-related gene (HERG) encodes potassium channels mediating the rapid delayed-rectifier K+ current, IKr, vital for normal repolarization of the heart's ventricles. Consequently, HERG is a pharmacological target for class Ia and III antiarrhythmic drugs.<xref ref-type="bibr" rid="article-29236.r13">[13]</xref>&#x000a0;</p>
        <p>Class III agents now include voltage-dependent K+&#x000a0;channel blockers, categorized as class IIIa, which include nonselective agents, such as amiodarone, and selective agents, such as sotalol, acting on the HERG channel. Blockade of the Kv11.1 (HERG) channel-mediated rapid K+ current (IKr) leads to prolonged action potential recovery in atrial, Purkinje, and ventricular myocytes, resulting in increased effective refractory period, prolonged action potential recovery time, and consequently decreased reentrant tendency.<xref ref-type="bibr" rid="article-29236.r14">[14]</xref></p>
        <p>
<bold>Pharmacokinetics&#x000a0;</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;The bioavailability&#x000a0;is 95% to 100% without the hepatic first-pass effect (metabolism). After a single oral dosage,&#x000a0;the drug takes about 2.5 to 3 hours to reach its maximum (peak) serum concentration. On the other hand, the IV infusion takes around 2 hours to attain peak serum levels.&#x000a0;IV administration of sotalol reduces the time required to reach steady-state plasma concentration from 3 days to just 1&#x000a0;to 2 days, which includes a single IV dose followed by 1&#x000a0;or 2 oral doses.<xref ref-type="bibr" rid="article-29236.r15">[15]</xref></p>
        <p><bold>Distribution:</bold>&#x000a0;The drug is water-soluble, which results in minimal&#x000a0;blood-brain barrier penetration.&#x000a0;Sotalol is distributed to the heart, liver, and kidneys.</p>
        <p><bold>Metabolism:&#x000a0;</bold>&#x000a0;Hepatic metabolism of sotalol is minimal; sotalol has no active metabolites.<xref ref-type="bibr" rid="article-29236.r16">[16]</xref></p>
        <p><bold>Elimination:</bold>&#x000a0;Sotalol&#x000a0;is eliminated primarily&#x000a0;from the kidneys, with up to 20% excreted in the feces.&#x000a0;The drug's half-life is 10 to 20 hours in a population with normal renal function.<xref ref-type="bibr" rid="article-29236.r17">[17]</xref></p>
      </sec>
      <sec id="article-29236.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Sotalol is available both in&#x000a0;oral and&#x000a0;IV formulations. Dilute&#x000a0;IV sotalol in normal saline, Ringer lactate, or D5W to achieve a concentration of (15 mg/mL). There is a dosage conversion between oral and&#x000a0;IV sotalol. Oral sotalol 80 mg is equivalent to 75 mg of IV; 160 mg oral is equivalent to 150 mg of IV. If infusing IV, the recommendation is to administer the drug slowly, as a rapid infusion can cause hypotension.<xref ref-type="bibr" rid="article-29236.r18">[18]</xref></p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>The most effective dosage for preventing atrial fibrillation is 120 mg twice daily, depending on renal function. No statistically significant difference between&#x000a0;IV and oral sotalol is evident in different parameters such as prolonged QT&#x000a0;interval,&#x000a0;atrial effective refractory period and right ventricular effective refractory period, sinus cycle length, and atrioventricular node relative&#x000a0;and functional refractory periods.<xref ref-type="bibr" rid="article-29236.r19">[19]</xref>&#x000a0;According to the American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS) guidelines, sotalol is ineffective for converting atrial fibrillation to sinus rhythm but can be used for atrial fibrillation recurrence prophylaxis. Sotalol achieves 30% to 50% success rates in maintaining sinus rhythm over&#x000a0;1 year.<xref ref-type="bibr" rid="article-29236.r20">[20]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment:</bold>&#x000a0;Sotalol&#x000a0;is&#x000a0;excreted mainly through the kidneys. Therefore, dose&#x000a0;adjustment&#x000a0;is required if the&#x000a0;estimated glomerular rate (eGFR) is less than 60 mL/min.&#x000a0;The recommended initial dose of sotalol is 80 mg, given twice daily if GFR&#x000a0;is more than&#x000a0;60 mL/min, with the dose increased (generally&#x000a0;allowing 2 to 3 days between dosing increments),&#x000a0;up to 320 mg, given in 2 or 3 divided doses.<xref ref-type="bibr" rid="article-29236.r21">[21]</xref>&#x000a0; Sotalol should be prescribed daily if the creatinine clearance (CrCl) is between 40 and 60 mL/min. Data suggest that the patient population with heart failure also needs a dosage adjustment.<xref ref-type="bibr" rid="article-29236.r22">[22]</xref>&#x000a0;The most effective dosage for preventing atrial fibrillation is 120 mg twice daily, depending on renal function.</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;No alteration in the clearance of sotalol is apparent in patients with hepatic impairment.</p>
        <p><bold>Pregnancy considerations:</bold> Half-life decreases to 10 hours in pregnancy due to the increased glomerular filtration rate. Data show that sotalol should be avoided during pregnancy. Sotalol&#x000a0;is teratogenic and not often the first choice in pregnant females. Close fetal monitoring is necessary when used.<xref ref-type="bibr" rid="article-29236.r12">[12]</xref><xref ref-type="bibr" rid="article-29236.r23">[23]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Sotalol is extensively excreted into breast milk and has minimal safety data in breastfed infants. Other drugs are preferred to sotalol, especially when patients are nursing a newborn or preterm infant.<xref ref-type="bibr" rid="article-29236.r24">[24]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>For children aged 2 and older with normal renal function, the initial dosing of sotalol is 1.2 mg/kg&#x000a0;3 times (3.6 mg/kg total daily dose). The maximum dose is 2.4 mg/kg&#x000a0;3 times daily (360 mg total daily). Dosing should be guided by clinical response, heart rate, and QTc interval&#x02014;increased doses preferably in a hospital setting, allowing at least 36 hours between increments. A nomogram should determine the appropriate pediatric sotalol dosage for children aged&#x000a0;2 or younger.&#x000a0;In a multicentered registry study, IV sotalol was evaluated in pediatric patients, including those with congenital heart disease and severe myocardial dysfunction.</p>
        <p>The typical acute and maintenance treatment dose was 1 mg/kg over approximately 60 minutes. Out of 85 patients, 79 were treated with IV sotalol for SVT, while 4 for ventricular arrhythmias. The study found that 49% of patients had successful termination of arrhythmia, and another 30% experienced improvement in rhythm control. In addition, QTc prolongation (&#x0003e;465 milliseconds) occurred in 16% of patients. IV sotalol demonstrated safety and effectiveness in treating tachyarrhythmias in pediatric patients.<xref ref-type="bibr" rid="article-29236.r25">[25]</xref></p>
        <p><bold>Older patients: </bold>Impaired renal function in older patients can result in an extended terminal elimination half-life of sotalol, leading to elevated drug levels. As sotalol is predominantly excreted through the kidneys,&#x000a0;the drug should be used cautiously in older adults with reduced renal clearance.<xref ref-type="bibr" rid="article-29236.r26">[26]</xref></p>
      </sec>
      <sec id="article-29236.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Sotalol's adverse effect profile is inherent in&#x000a0;the mechanisms of action as both a potassium channel blocker and a non-cardioselective &#x003b2;-blocker. The potassium channel blockade, primarily in phase 3 of the cardiac action potential, prolongs the QTc. Thus, the electrocardiogram (ECG) must be monitored upon initiating sotalol or adding other QTc-prolonging medications. Prolongation&#x000a0;of the QT&#x000a0;interval occurs in 1% to 2% of cases, which could lead to torsades de pointes or new ventricular tachycardia/ventricular fibrillation.&#x000a0;</p>
        <p>The adverse effect of&#x000a0;sotalol&#x000a0;on QT&#x000a0;prolongation is directly related to serum levels.<xref ref-type="bibr" rid="article-29236.r18">[18]</xref>&#x000a0;The adverse effects, especially torsades de pointes, are also dose-dependent;&#x000a0;the rate of torsades is 1% with doses less than 320 mg and increases up to 5% at doses of more than 320 mg.&#x000a0;Higher doses are possible if a patient has an implantable ICD. The incidence of QT prolongation occurs more frequently with IV formulation.</p>
        <p>Other adverse effects associated with the&#x000a0;non-cardioselective &#x003b2;-blockade include bradycardia, fatigue, dyspnea, and worsening heart failure. According to AHA/ACC 2022 guidelines, sotalol should be avoided in decompensated heart failure due to&#x000a0;its pro-arrhythmogenic properties and &#x003b2;-blockade.<xref ref-type="bibr" rid="article-29236.r27">[27]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Sotalol is not susceptible to pharmacokinetic drug interactions involving the cytochrome P450 system, as it does not undergo hepatic metabolism.&#x000a0;Pharmacodynamic interactions are given below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Digoxin: Digoxin and sotalol slow AV conduction and decrease heart rate, increasing the risk of bradycardia with concomitant use.<xref ref-type="bibr" rid="article-29236.r28">[28]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Calcium channel blockers (CCB): Combining sotalol and CCBs can reduce atrioventricular conduction, adversely affecting ventricular function and blood pressure.<xref ref-type="bibr" rid="article-29236.r29">[29]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Insulin and oral hypoglycemics: &#x003b2;-blockers, including sotalol, may mask symptoms of hypoglycemia. Conversely, their use may also lead to hyperglycemia, necessitating dose adjustments of insulin and antidiabetic drugs.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clonidine: Coadministration of sotalol increases the risk of bradycardia. To mitigate the risk of rebound hypertension, sotalol should be withdrawn several days before gradually discontinuing clonidine.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>&#x003b2;-2 agonists: Concomitant use of sotalol with albuterol, terbutaline, and isoproterenol may require increased dosages.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Catecholamine-depleting agents: Concurrent use of reserpine and guanethidine with &#x003b2;-blockers may result in a disproportionate decrease in sympathetic nervous tone, leading to hypotension, significant bradycardia, and syncope. Close monitoring is advised.<xref ref-type="bibr" rid="article-29236.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Food Interactions</bold>
</p>
        <p>Coadministration of food or antacids with sotalol may result in a slight decrease in plasma concentrations.<xref ref-type="bibr" rid="article-29236.r31">[31]</xref>&#x000a0;</p>
        <p>
<bold>Drug-Laboratory Test Interactions</bold>
</p>
        <p>Sotalol in the urine may yield falsely elevated levels of urinary metanephrine when measured by fluorimetric or photometric methods.<xref ref-type="bibr" rid="article-29236.r32">[32]</xref></p>
      </sec>
      <sec id="article-29236.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warning</bold>
</p>
        <p><bold>Life-threatening proarrythmias:&#x000a0;</bold>To reduce the risk of drug-induced arrhythmia, start sotalol in a facility that can provide continuous ECG monitoring and cardiac resuscitation. Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation. If the QT interval is &#x02265;500 ms, decrease the dose, increase the dosing interval, or discontinue the drug. Before starting sotalol, calculate&#x000a0;CrCl to determine the appropriate dosing.&#x000a0;Drug isomers may differ in their risk of pro-arrhythmia. For example, sotalol, an antiarrhythmic drug, has d- and l- enantiomers. A recent molecular dynamics study found that d-sotalol has a higher pro-arrhythmia risk of d-sotalol than l-sotalol.<xref ref-type="bibr" rid="article-29236.r13">[13]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>
<bold>Contraindications related to non-cardioselective &#x003b2;-blockade:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bronchial asthma or other&#x000a0;bronchospastic&#x000a0;conditions&#x000a0;<xref ref-type="bibr" rid="article-29236.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sinus bradycardia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Second- or third-degree&#x000a0;AV block absent a functioning pacemaker</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cardiogenic shock</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Decompensated heart failure due to a negative inotropic effect&#x000a0;<xref ref-type="bibr" rid="article-29236.r27">[27]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sick sinus syndrome (without a pacemaker)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Labile diabetes&#x000a0;(due to hypoglycemia)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Left ventricular hypertrophy&#x000a0;(which also increases the risk of arrhythmia)&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Contraindications related to QTc prolonging effects:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CrCl less than 40 mL/min when used for atrial fibrillation or flutter</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acquired or congenital long QTc syndromes</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Uncorrected hypokalemia or hypomagnesemia (increased risk of prolonging&#x000a0;QT&#x000a0; and causing torsades de pointes)</p>
          </list-item>
        </list>
        <p><bold>Other contraindications: </bold>They include previous evidence of sotalol hypersensitivity or allergy.<xref ref-type="bibr" rid="article-29236.r34">[34]</xref></p>
      </sec>
      <sec id="article-29236.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients initiated on sotalol should be hospitalized&#x000a0;for at least&#x000a0;3 days with cardiac rhythm monitoring and assessment.&#x000a0;Blood pressure&#x000a0;and&#x000a0;heart rate require monitoring. Sotalol should not be initiated with a baseline QTc greater than 450 ms. Providers should have&#x000a0;magnesium over 2 mEq/L and potassium greater than 4 mEq/L available when patients receive sotalol. Serum creatinine should be measured, and the dose requires adjustment according to renal function. The&#x000a0;recommendation is that the dose of sotalol should be gradually increased over&#x000a0;3 days. Most cardiologists recommend observing the patient in a hospital with serial ECGs for at least&#x000a0;3 days after starting sotalol.<xref ref-type="bibr" rid="article-29236.r35">[35]</xref></p>
        <p>A study&#x000a0;demonstrated that outpatient initiation and maintenance of sotalol therapy for atrial fibrillation could be effectively monitored in carefully selected patients with cardiac implantable electronic devices equipped with continuous remote monitoring capabilities.<xref ref-type="bibr" rid="article-29236.r36">[36]</xref></p>
      </sec>
      <sec id="article-29236.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Sotalol toxicity is inherent due to&#x000a0;the mechanism of action as both a potassium channel blocker and a non-cardioselective &#x003b2;-blocker and mirrors&#x000a0;the adverse effect profile. The most obvious and potentially problematic sign of toxicity is concentration-related QTc prolongation. If QTc is over 500 ms during initiation, the sotalol dose should be reduced or discontinued. If QTc&#x000a0;exceeds 520 ms during the maintenance phase of dosing, the clinician should either reduce the dose or discontinue sotalol.</p>
        <p>In addition, therapeutic measures may be required according to the manufacturer's labeling in case of a massive overdose. Patients with bradycardia or cardiac asystole atropine or transvenous cardiac pacing are necessary. In addition, the bronchospasm associated with &#x003b2;-blockage requires higher than normal &#x003b2;-2-agonist doses. Management of torsades de pointes is DC cardioversion, transvenous cardiac pacing, epinephrine, and magnesium sulfate. Hemodialysis can reduce sotalol plasma concentrations as sotalol does not bind to plasma protein. Due to the risk of torsades de pointes&#x000a0;and asystole, patients should be closely monitored until QT intervals are normalized and the heart rate is more than 50 bpm.</p>
        <p>A recent study evaluated&#x000a0;the drug-specific risk of&#x000a0;SQTP (severe QT prolongation) after an acute drug overdose. Sotalol was one of the most common drugs implicated in acute drug overdoses related to SQTP.<xref ref-type="bibr" rid="article-29236.r37">[37]</xref><bold>&#x000a0;</bold>According to the evidence-based consensus of the American Association of Poison Control Centers, ingesting sotalol exceeding 4 mg/kg indicates referral to the emergency department. For an asymptomatic patient who has unintentionally ingested sotalol, a minimum observation period of 12 hours is recommended.<xref ref-type="bibr" rid="article-29236.r38">[38]</xref><xref ref-type="bibr" rid="article-29236.r39">[39]</xref>&#x000a0;According to EXTRIP (Extracorporeal Treatments In Poisoning) guidelines, sotalol is dialyzable. Indications for extracorporeal treatments include refractory bradycardia,&#x000a0;recurrent torsades de pointes, and hypotension.<xref ref-type="bibr" rid="article-29236.r40">[40]</xref></p>
      </sec>
      <sec id="article-29236.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The effective initiation and monitoring of sotalol therapy require collaboration among an interprofessional healthcare team comprising cardiologists, clinicians, and pharmacists to minimize the risk of toxicity.&#x000a0;Without proper management, the risk of toxicity can increase.<xref ref-type="bibr" rid="article-29236.r22">[22]</xref>&#x000a0;Essential elements of coordinated care involve evaluating vital signs, electrolytes, and cardiac function, as well as monitoring for QTc changes and arrhythmias. Patient education, especially focusing on glucose monitoring for individuals with diabetes, is paramount. Pharmacists are integral in assessing drug interactions, making renal dosing adjustments, and providing medication education. Nurses contribute by identifying adverse events, reporting therapeutic effectiveness, and facilitating timely adjustments to therapy to ensure optimal outcomes while minimizing adverse effects.</p>
        <p>Care coordination involves the following steps:</p>
        <list list-type="bullet">
          <list-item>
            <p>Evaluating&#x000a0;blood pressure and heart rate before and after the initial dose, as well as after any dosage adjustments.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Obtaining serum creatinine, magnesium, and potassium levels.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Monitoring cardiac activity for QTc changes and arrhythmias.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Assessing cardiac and pulmonary status.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Providing guidance to patients with diabetes regarding the need for close monitoring of glucose levels due to potential alterations in glucose tolerance caused by &#x003b2;-blockers.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Assessing additional medications taken by the patient and considering alternative therapies or dosage adjustments, as necessary.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ensuring the involvement of a pharmacist to evaluate drug interactions, make renal dose adjustments, and provide medication education.</p>
          </list-item>
        </list>
        <p>A board-certified pharmacist specializing in cardiology can assist the clinical team with sotalol dosing and monitoring. Nurses should familiarize themselves with the signs of adverse events linked to sotalol administration and report the effectiveness of the regimen to enable necessary therapy adjustments. Adopting an interprofessional team approach to sotalol usage facilitates achieving optimal outcomes while minimizing adverse effects.&#x000a0;</p>
      </sec>
      <sec id="article-29236.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29236&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29236">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29236/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29236">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29236.s11">
        <title>References</title>
        <ref id="article-29236.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>deSouza</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Martindale</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sinert</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Antidysrhythmic drug therapy for the termination of stable, monomorphic ventricular tachycardia: a systematic review.</article-title>
            <source>Emerg Med J</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-7</page-range>
            <pub-id pub-id-type="pmid">24042252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zimetbaum</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Josephson</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Amiodarone versus sotalol for atrial fibrillation.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Aug</month>
            <day>11</day>
            <volume>353</volume>
            <issue>6</issue>
            <fpage>627</fpage>
            <page-range>627-30; author reply 627-30</page-range>
            <pub-id pub-id-type="pmid">16094764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feuerborn</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Dechand</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vadlamudi</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Torre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Groh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Navaravong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ranjan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Varela</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bunch</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Protocol Development and Initial Experience With Intravenous Sotalol Loading for Atrial Arrhythmias.</article-title>
            <source>Crit Pathw Cardiol</source>
            <year>2023</year>
            <month>Mar</month>
            <day>01</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">36812336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Askins</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Keefe</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Somberg</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Haft</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Lessem</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: a double-blind, randomized, placebo-controlled evaluation of two doses.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1986</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>752</fpage>
            <page-range>752-62</page-range>
            <pub-id pub-id-type="pmid">2428852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McNamara</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Tamariz</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Bass</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography.</article-title>
            <source>Ann Intern Med</source>
            <year>2003</year>
            <month>Dec</month>
            <day>16</day>
            <volume>139</volume>
            <issue>12</issue>
            <fpage>1018</fpage>
            <page-range>1018-33</page-range>
            <pub-id pub-id-type="pmid">14678922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gomes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ip</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Santoni-Rugiu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ergin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lansman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Newhouse</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>334</fpage>
            <page-range>334-9</page-range>
            <pub-id pub-id-type="pmid">10440141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moon-Grady</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhogal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Tacy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hornberger</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of sotalol as first-line therapy for fetal supraventricular tachyarrhythmias.</article-title>
            <source>Am J Cardiol</source>
            <year>2012</year>
            <month>Jun</month>
            <day>01</day>
            <volume>109</volume>
            <issue>11</issue>
            <fpage>1614</fpage>
            <page-range>1614-8</page-range>
            <pub-id pub-id-type="pmid">22444730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Somberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Molnar</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Sotalol versus Amiodarone in Treatment of Atrial Fibrillation.</article-title>
            <source>J Atr Fibrillation</source>
            <year>2016</year>
            <season>Feb-Mar</season>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>1359</fpage>
            <pub-id pub-id-type="pmid">27909477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Reda</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>XC</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Atwood</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Raisch</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>MD</given-names>
              </name>
              <collab>Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators</collab>
            </person-group>
            <article-title>Amiodarone versus sotalol for atrial fibrillation.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>May</month>
            <day>05</day>
            <volume>352</volume>
            <issue>18</issue>
            <fpage>1861</fpage>
            <page-range>1861-72</page-range>
            <pub-id pub-id-type="pmid">15872201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Towbin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Darrieux</surname>
                <given-names>FCC</given-names>
              </name>
              <name>
                <surname>Daubert</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>de Chillou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePasquale</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Estes</surname>
                <given-names>NAM</given-names>
              </name>
              <name>
                <surname>Hua</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Indik</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ingles</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Judge</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Keegan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Krahn</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>FI</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Mestroni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Priori</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Saffitz</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Sanatani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>van Tintelen</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Wilde</surname>
                <given-names>AAM</given-names>
              </name>
              <name>
                <surname>Zareba</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy.</article-title>
            <source>Heart Rhythm</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>11</issue>
            <fpage>e301</fpage>
            <page-range>e301-e372</page-range>
            <pub-id pub-id-type="pmid">31078652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lakkireddy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bawa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bush</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Charate</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bommana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pothineni</surname>
                <given-names>NVK</given-names>
              </name>
              <name>
                <surname>Kabra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Darden</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koreber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tummala</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vasamreddy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mohanty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gopinathannair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Natale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Feasibility and Safety of Intravenous Sotalol Loading in Adult Patients With&#x000a0;Atrial Fibrillation (DASH-AF).</article-title>
            <source>JACC Clin Electrophysiol</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>555</fpage>
            <page-range>555-564</page-range>
            <pub-id pub-id-type="pmid">37014289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batul</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Gopinathannair</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Intravenous Sotalol - Reintroducing a Forgotten Agent to the Electrophysiology Therapeutic Arsenal.</article-title>
            <source>J Atr Fibrillation</source>
            <year>2017</year>
            <season>Feb-Mar</season>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>1499</fpage>
            <pub-id pub-id-type="pmid">29250266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeMarco</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Furutani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>JRD</given-names>
              </name>
              <name>
                <surname>Jeng</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Fettinger</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Bekker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ngo</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Noskov</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Yarov-Yarovoy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sack</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Wulff</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Vorobyov</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Molecular determinants of pro-arrhythmia proclivity of d- and l-sotalol via a multi-scale modeling pipeline.</article-title>
            <source>J Mol Cell Cardiol</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>158</volume>
            <fpage>163</fpage>
            <page-range>163-177</page-range>
            <pub-id pub-id-type="pmid">34062207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Terrar</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Modernized Classification of Cardiac Antiarrhythmic Drugs.</article-title>
            <source>Circulation</source>
            <year>2018</year>
            <month>Oct</month>
            <day>23</day>
            <volume>138</volume>
            <issue>17</issue>
            <fpage>1879</fpage>
            <page-range>1879-1896</page-range>
            <pub-id pub-id-type="pmid">30354657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varela</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Burnham</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>T May</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>L Bair</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>B Muhlestein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>L Anderson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>U Knowlton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jared Bunch</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Economics and outcomes of sotalol in-patient dosing approaches in patients with atrial fibrillation.</article-title>
            <source>J Cardiovasc Electrophysiol</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>333</fpage>
            <page-range>333-342</page-range>
            <pub-id pub-id-type="pmid">34953091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Sotalol</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">31643586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanyok</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of sotalol.</article-title>
            <source>Am J Cardiol</source>
            <year>1993</year>
            <month>Aug</month>
            <day>12</day>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>19A</fpage>
            <page-range>19A-26A</page-range>
            <pub-id pub-id-type="pmid">8346722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samanta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thiagalingam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lakkireddy</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kovoor</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The Use of Intravenous Sotalol in Cardiac Arrhythmias.</article-title>
            <source>Heart Lung Circ</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>1318</fpage>
            <page-range>1318-1326</page-range>
            <pub-id pub-id-type="pmid">29853342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kopelman</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Woosley</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Roden</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Echt</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease.</article-title>
            <source>Am J Cardiol</source>
            <year>1988</year>
            <month>May</month>
            <day>01</day>
            <volume>61</volume>
            <issue>13</issue>
            <fpage>1006</fpage>
            <page-range>1006-11</page-range>
            <pub-id pub-id-type="pmid">3284316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>January</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Wann</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Alpert</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cigarroa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ellinor</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Sacco</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Tchou</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>ACC/AHA Task Force Members</collab>
            </person-group>
            <article-title>2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Dec</month>
            <day>02</day>
            <volume>130</volume>
            <issue>23</issue>
            <fpage>e199</fpage>
            <page-range>e199-267</page-range>
            <pub-id pub-id-type="pmid">24682347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Prystowsky</surname>
                <given-names>EN</given-names>
              </name>
            </person-group>
            <article-title>Sotalol: An important new antiarrhythmic.</article-title>
            <source>Am Heart J</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>137</volume>
            <issue>3</issue>
            <fpage>388</fpage>
            <page-range>388-409</page-range>
            <pub-id pub-id-type="pmid">10047618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finks</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Manguso</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Assessment of sotalol prescribing in a community hospital: opportunities for clinical pharmacist involvement.</article-title>
            <source>Int J Pharm Pract</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>281</fpage>
            <page-range>281-6</page-range>
            <pub-id pub-id-type="pmid">21733016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Hare</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Murnaghan</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Leahey</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Varma</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>McDevitt</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Sotalol as a hypotensive agent in pregnancy.</article-title>
            <source>Br J Obstet Gynaecol</source>
            <year>1980</year>
            <month>Sep</month>
            <volume>87</volume>
            <issue>9</issue>
            <fpage>814</fpage>
            <page-range>814-20</page-range>
            <pub-id pub-id-type="pmid">7426541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <chapter-title>Sotalol</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malloy-Walton</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Von Bergen</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Balaji</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fischbach</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Garnreiter</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Asaki</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Moak</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ochoa</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Kirk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Avari Silva</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Saul</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>IV Sotalol Use in Pediatric and Congenital Heart Patients: A Multicenter Registry Study.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>11</volume>
            <issue>9</issue>
            <fpage>e024375</fpage>
            <pub-id pub-id-type="pmid">35491986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ayan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pothineni</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>Siraj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Cardiac drug therapy-considerations in the elderly.</article-title>
            <source>J Geriatr Cardiol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>992</fpage>
            <page-range>992-997</page-range>
            <pub-id pub-id-type="pmid">28321243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>79</volume>
            <issue>17</issue>
            <fpage>e263</fpage>
            <page-range>e263-e421</page-range>
            <pub-id pub-id-type="pmid">35379503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Kam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nordin</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Khelae</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study.</article-title>
            <source>J Geriatr Cardiol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>749</fpage>
            <page-range>749-759</page-range>
            <pub-id pub-id-type="pmid">27899939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Handler</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects using combined rate-slowing antihypertensive agents.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>529</fpage>
            <page-range>529-32</page-range>
            <pub-id pub-id-type="pmid">21762367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lobay</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Rauwolfia in the Treatment of Hypertension.</article-title>
            <source>Integr Med (Encinitas)</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>40</fpage>
            <page-range>40-6</page-range>
            <pub-id pub-id-type="pmid">26770146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mar</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Horbal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Dukes</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lakkireddy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GYH</given-names>
              </name>
              <name>
                <surname>Miletello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Noseworthy</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Reiffel</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tisdale</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Olshansky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gopinathannair</surname>
                <given-names>R</given-names>
              </name>
              <collab>from the American Heart Association Electrocardiography and Arrhythmias Committee of the Council of Clinical Cardiology</collab>
            </person-group>
            <article-title>Drug Interactions Affecting Antiarrhythmic Drug Use.</article-title>
            <source>Circ Arrhythm Electrophysiol</source>
            <year>2022</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>e007955</fpage>
            <pub-id pub-id-type="pmid">35491871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joyce</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Melvin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Shea</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Costelloe</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>O'Halloran</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Case report of a phantom pheochromocytoma.</article-title>
            <source>Biochem Med (Zagreb)</source>
            <year>2020</year>
            <month>Jun</month>
            <day>15</day>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>021003</fpage>
            <pub-id pub-id-type="pmid">32550819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zimetbaum</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Antiarrhythmic drug therapy for atrial fibrillation.</article-title>
            <source>Circulation</source>
            <year>2012</year>
            <month>Jan</month>
            <day>17</day>
            <volume>125</volume>
            <issue>2</issue>
            <fpage>381</fpage>
            <page-range>381-9</page-range>
            <pub-id pub-id-type="pmid">22249528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tatu</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Elisei</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Chioncel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Miulescu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nwabudike</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Immunologic adverse reactions of &#x003b2;-blockers and the skin.</article-title>
            <source>Exp Ther Med</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>955</fpage>
            <page-range>955-959</page-range>
            <pub-id pub-id-type="pmid">31384329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biswas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tarakji</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Noseworthy</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Newton-Cheh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Multicenter Analysis of Dosing Protocols for Sotalol Initiation.</article-title>
            <source>J Cardiovasc Pharmacol Ther</source>
            <year>2020</year>
            <month>May</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>212</fpage>
            <page-range>212-218</page-range>
            <pub-id pub-id-type="pmid">31707834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mascarenhas</surname>
                <given-names>DAN</given-names>
              </name>
              <name>
                <surname>Mudumbi</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Kantharia</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Outpatient Initiation of Sotalol in Patients with Atrial Fibrillation: Utility of Cardiac Implantable Electronic Devices for Therapy Monitoring.</article-title>
            <source>Am J Cardiovasc Drugs</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>693</fpage>
            <page-range>693-700</page-range>
            <pub-id pub-id-type="pmid">34291437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campleman</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Brent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pizon</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Shulman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wax</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Manini</surname>
                <given-names>AF</given-names>
              </name>
              <collab>Toxicology Investigators&#x02019; Consortium (ToxIC)</collab>
            </person-group>
            <article-title>Drug-specific risk of severe QT prolongation following acute drug overdose.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>58</volume>
            <issue>12</issue>
            <fpage>1326</fpage>
            <page-range>1326-1334</page-range>
            <pub-id pub-id-type="pmid">32252558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wax</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Erdman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Chyka</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Keyes</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Caravati</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Booze</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Christianson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Woolf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Manoguerra</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Scharman</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Troutman</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>beta-blocker ingestion: an evidence-based consensus guideline for out-of-hospital management.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2005</year>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>131</fpage>
            <page-range>131-46</page-range>
            <pub-id pub-id-type="pmid">15906457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gummin</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Mowry</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Beuhler</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Dibert</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Rivers</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>NPT</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>58</volume>
            <issue>12</issue>
            <fpage>1360</fpage>
            <page-range>1360-1541</page-range>
            <pub-id pub-id-type="pmid">33305966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29236.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouchard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nolin</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ghannoum</surname>
                <given-names>M</given-names>
              </name>
              <collab>EXTRIP workgroup</collab>
            </person-group>
            <article-title>Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.</article-title>
            <source>Crit Care</source>
            <year>2021</year>
            <month>Jun</month>
            <day>10</day>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>201</fpage>
            <pub-id pub-id-type="pmid">34112223</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
